Nautilus Biotechnology Reports Q3 2025 Financial Results with Improved Net Loss

Nautilus Biotechnology, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $13.6 million, a 17% improvement compared to a net loss of $16.4 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $45.2 million, down from $53.2 million in the prior year, reflecting a 15% reduction. The decrease in losses is attributed to lower operating expenses, which totaled $15.5 million for the quarter, down 19% from $19.1 million in Q3 2024, and $51.4 million for the nine-month period, a 16% decrease from $61.5 million in the previous year.

The company’s operating expenses were primarily driven by research and development (R&D) costs, which decreased to $9.6 million in Q3 2025 from $12.3 million in Q3 2024, and to $31.5 million for the nine months, down from $37.7 million. This reduction was largely due to operational efficiencies and a reduction in workforce implemented in March 2025. General and administrative expenses also saw a decline, totaling $5.9 million for the quarter and $19.9 million for the nine months, both reflecting decreases from the previous year.

Nautilus continues to focus on the development of its proteomics platform, which remains in the development stage. The company has not yet generated any revenue from product sales, as it is still working on establishing its technology and commercial infrastructure. As of September 30, 2025, Nautilus had cash, cash equivalents, and short-term investments totaling $131.4 million, which management believes will be sufficient to fund operations for at least the next twelve months. The company has also indicated plans to launch early access to its platform in the first half of 2026, targeting specific assays related to Alzheimer’s disease.

In terms of operational metrics, Nautilus reported a total of 126.3 million shares outstanding as of the end of September 2025. The company has been actively managing its capital structure, including a recent transfer of its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, which provides an additional 180 days to regain compliance with the minimum bid price requirement. The company is also exploring various funding options, including potential equity offerings, to support its ongoing development and commercialization efforts.

Looking ahead, Nautilus anticipates continued significant operating losses as it invests in R&D and builds its commercial capabilities. The company is committed to advancing its proteomics platform and establishing a market presence, but acknowledges the challenges of securing additional funding and navigating a competitive landscape. The successful commercialization of its technology will depend on ongoing development efforts and market acceptance, with the company emphasizing the need for substantial additional capital to achieve its long-term objectives.